10-Q: Inhibikase Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Inhibikase Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and ongoing development of its drug candidates.

Summary

• Inhibikase Therapeutics, a clinical-stage pharmaceutical company, reported its financial results for the second quarter of 2024.
• The company is focused on developing protein kinase inhibitor therapeutics for Parkinson's disease and related disorders.
• The Phase 2 program for Risvodetinib (IkT-148009) in Parkinson's disease, known as the 201 trial, was fully enrolled in June 2024.
• The company is also developing IkT-001Pro, a prodrug of imatinib mesylate, for the treatment of Stable Phase Chronic Myelogenous Leukemia (SP-CML) and is exploring its use in pulmonary arterial hypertension (PAH).
• The company's working capital at June 30, 2024, was $4,898,258, with cash and cash equivalents of $3,086,455 and marketable securities of $4,853,559.
• The company reported a net loss of $9,609,243 for the six months ended June 30, 2024.
• The company estimates its current working capital will fund operations into December 2024.
• The company is facing a legal claim from Pivot Holding LLC seeking $1.625 million in milestone payments plus interest, which the company is disputing.
• The company has identified a material weakness in its internal control over financial reporting related to the calculation of net loss per share.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and drug development, the company's financial situation and legal challenges raise significant concerns. The material weakness in internal controls is also a negative factor.

Positives

• The 201 trial for Parkinson's disease is fully enrolled, indicating progress in clinical development.
• The company has established bioequivalence for a 600mg dose of IkT-001Pro to 400mg of imatinib mesylate.
• The company is actively engaging with the FDA on regulatory pathways for its drug candidates.
• The company has a strong patent portfolio, providing intellectual property protection for its assets.
• The company has developed a tablet formulation for Risvodetinib (IkT-148009) that improves drug delivery.
• The company has received Orphan Drug Designation from the FDA for Risvodetinib (IkT-148009) for the treatment of MSA.

Negatives

• The company has incurred significant net losses since its inception and anticipates continuing to incur net losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's working capital is estimated to be sufficient only until December 2024.
• The company is facing a legal claim for $1.625 million plus interest.
• The company has identified a material weakness in its internal control over financial reporting.
• The company's grant revenue has decreased to $0 for the three and six months ended June 30, 2024.

Risks

• The company's future success depends on its ability to raise additional capital.
• The company is subject to risks related to drug development, regulatory approval, and market acceptance.
• The company may face further clinical holds by the FDA in the future.
• The company's clinical trials may reveal significant adverse events or side effects.
• The company's business is highly dependent on the success of its initial product candidates.
• The company may encounter delays in its current and planned clinical trials.
• The company's product candidates may not achieve market acceptance.
• The company is dependent on third-party suppliers for key raw materials.
• The company has identified a material weakness in its internal control over financial reporting which could adversely affect the business.

Future Outlook

The company anticipates costs and expenses to increase as it continues to develop its product candidates and may seek to fund its operations through additional public equity, private equity, or debt financings. The company estimates its working capital will fund operations into December 2024. The company plans to submit regulatory documents for Risvodetinib (IkT-148009) to European Union authorities in 2024. The company plans to introduce the tablet formulation of Risvodetinib (IkT-148009) into the 12-month extension study.

Management Comments

• Management believes that Risvodetinib (IkT-148009) can modify the course of Parkinson's disease.
• Management believes that the 505(b)(2) pathway appears to be the appropriate pathway for approval of IkT-001Pro.
• Management plans to evaluate imatinib delivered by IkT-001Pro for PAH.
• Management believes that the multi-decade failures in the treatment of neurodegenerative diseases such as PD result from a lack of understanding of the biochemistry of the disease processes involved.
• Management believes its approach to PD and other neurological diseases has identified the underlying cause of disease.

Industry Context

The company is operating in the competitive pharmaceutical industry, specifically targeting neurodegenerative diseases, an area with high unmet medical needs. The company's approach to understanding the underlying biochemistry of diseases and developing targeted therapies differentiates it from some competitors. The company is also exploring the use of its drug candidates in orphan indications, which may provide market exclusivity and faster regulatory pathways.

Comparison to Industry Standards

• The company's focus on protein kinase inhibitors aligns with a growing trend in drug development for neurological disorders.
• The company's approach to drug delivery, such as the development of a tablet formulation for Risvodetinib, is consistent with industry efforts to improve patient outcomes.
• The company's use of the 505(b)(2) regulatory pathway for IkT-001Pro is a common strategy for companies developing new formulations of existing drugs.
• The company's financial position, with a limited cash runway and ongoing losses, is not uncommon for clinical-stage biotech companies.
• The company's patent portfolio is a key asset, providing a competitive advantage in the market.
• The company's clinical trial design, including the use of placebo controls and multiple endpoints, is consistent with industry best practices.

Legal Proceedings

• The company is facing a demand for arbitration from Pivot Holding LLC, alleging breach of contract and seeking $1.625 million in milestone payments plus interest.
• The company has filed a counterclaim against Sphaera Pharma Pte. Ltd. for over $900,000 in damages.

Related Party Transactions

• During the three and six months ended June 30, 2024, the Company incurred expenses of approximately $175 thousand and $297 thousand, respectively, with a related party vendor included in research and development expenses.
• As at the period ended June 30, 2024 and December 31, 2023, the Company had a payable or accrued expense balance with a related party vendor of approximately $125 thousand and $57 thousand, respectively, included in accounts payable and accrued expenses.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity offerings.
• Employees may be affected by potential cost-cutting measures or delays in research projects.
• Patients may benefit from the development of new therapies for Parkinson's disease, MSA, CML and PAH.
• Creditors face the risk of non-payment if the company is unable to raise additional capital.
• Suppliers may be affected by potential delays in payments or changes in the company's operating plan.

Next Steps

• The company plans to report results from the 201 trial in the fourth quarter of 2024.
• The company plans to extend the 201 trial by up to 12 months subject to additional financing.
• The company plans to submit regulatory documents for Risvodetinib (IkT-148009) to European Union authorities in 2024.
• The company plans to introduce the tablet formulation of Risvodetinib (IkT-148009) into the 12-month extension study.
• The company will continue to evaluate IkT-001Pro for PAH.
• The company will continue to work with the National Institute of Neurological Diseases and Stroke to possibly initiate a Phase 2/3 program to evaluate Risvodetinib (IkT-148009) as a treatment for MSA.
• The company will continue to evaluate higher doses of IkT-001Pro to cover the full range of doses approved for imatinib mesylate.

Key Dates

Keywords

Parkinson's disease, Risvodetinib, IkT-148009, IkT-001Pro, imatinib mesylate, Multiple System Atrophy, Chronic Myelogenous Leukemia, Pulmonary Arterial Hypertension, clinical trials, drug development, pharmaceutical, biotechnology, FDA, regulatory approval, kinase inhibitor